In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From argenx N.V.

Can UCB Make Its Mark In Myasthenia Gravis?

The Belgian drugmaker has presented positive data on its two submission-ready generalized myasthenia gravis drugs zilucoplan and rozanolixizumab but analysts are concerned that their efficacy will not differentiate them sufficiently to challenge Vyvgart and Soliris/Ultomiris.

Rare Diseases Clinical Trials

Analysts Admire Argenx's Vyvgart Launch

The generalized myasthenia gravis-approved drug passed the $20m mark in sales for the first quarter, comfortably surpassing analyst estimates.

Launches Sales & Earnings

Finance Watch: Public Markets Open Back Up For Biopharma Offerings

Public Company Edition: An IPO and three big follow-on offerings hit the market but other public companies revealed plans to cut costs or reprioritize their R&D pipelines, signaling that uncertainty remains. 

Financing Strategy

Subcutaneous Efgartigimod Expands Payer Potential For Argenx’s Drug

With positive Phase III data for the injectable version of its myasthenia gravis therapy, the company expects most patients to use it over intravenous Vyvgart, opening more avenues for reimbursement.

Immune Disorders Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Other Names / Subsidiaries
    • arGEN-X N.V.
UsernamePublicRestriction

Register